{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:27:18Z","timestamp":1791649638551,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K15386"],"award-info":[{"award-number":["21K15386"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Seiichi Imai Memorial Foundation"},{"name":"Intelligent Cosmos Academic Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ovarian cancer has the worst outcome among gynecological malignancies; therefore, biomarkers that could contribute to the early diagnosis and\/or prognosis prediction are urgently required. In the present study, we focused on the secreted protein spondin-1 (SPON1) and clarified the prognostic relevance in ovarian cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We developed a monoclonal antibody (mAb) that selectively recognizes SPON1. Using this specific mAb, we determined the expression of SPON1 protein in the normal ovary, serous tubal intraepithelial carcinoma (STIC), and ovarian cancer tissues, as well as in various normal adult tissues by immunohistochemistry, and verified its clinicopathological significance in ovarian cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The normal ovarian tissue was barely positive for SPON1, and no immunoreactive signals were detected in other healthy tissues examined, which was in good agreement with data obtained from gene expression databases. By contrast, upon semi-quantification, 22 of 242 ovarian cancer cases (9.1%) exhibited high SPON1 expression, whereas 64 (26.4%), 87 (36.0%), and 69 (28.5%) cases, which were designated as SPON1-low, possessed the moderate, weak, and negative SPON1 expression, respectively. The STIC tissues also possessed SPON1-positive signals. The 5-year recurrence-free survival (RFS) rate in the SPON1-high group (13.6%) was significantly lower than that in the SPON1-low group (51.2%). In addition, high SPON1 expression was significantly associated with several clinicopathological variables. Multivariable analysis revealed that high SPON1 was an independent prognostic factor for RFS of ovarian cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SPON1 represents a prognostic biomarker for ovarian cancer, and the anti-SPON1 mAb could be valuable as an outcome predictor.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13048-023-01180-8","type":"journal-article","created":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T05:02:23Z","timestamp":1683954143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["SPON1 is an independent prognostic biomarker for ovarian cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Ryoya","family":"Miyakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiya","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,13]]},"reference":[{"key":"1180_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"1180_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1180_CR3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. The Lancet. 2014;384:1376\u201388.","journal-title":"The Lancet"},{"key":"1180_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","volume":"43","author":"WG McCluggage","year":"2011","unstructured":"McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420\u201332.","journal-title":"Pathology"},{"key":"1180_CR5","volume-title":"World Cancer Report 2014","author":"BW Stewart","year":"2014","unstructured":"Stewart BW. World Cancer Report 2014. France: IARC Publications; 2014. 456 \u2013 81."},{"key":"1180_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc.2016.113","volume":"17","author":"AN Karnezis","year":"2017","unstructured":"Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer. 2017;17:65\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 2","key":"1180_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ijgo.12617","volume":"143","author":"J Prat","year":"2018","unstructured":"Prat J, Mutch DG. Pathology of cancers of the female genital tract including molecular pathology. Int J Gynaecol Obstet. 2018;143(Suppl 2):93\u2013108.","journal-title":"Int J Gynaecol Obstet"},{"key":"1180_CR8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"1180_CR9","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra1813254","volume":"380","author":"P Morice","year":"2019","unstructured":"Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Engl J Med. 2019;380:1256\u201366.","journal-title":"N Engl J Med"},{"key":"1180_CR10","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/S1470-2045(20)30533-7","volume":"21","author":"RP Rocconi","year":"2020","unstructured":"Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III\/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 2020;21:1661\u201372.","journal-title":"Lancet Oncol"},{"key":"1180_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres LC, Cushing-Haugen KL, Kobel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive epithelial ovarian Cancer survival by Histotype and Disease Stage. J Natl Cancer Inst. 2019;111:60\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1180_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0092-8674(92)90121-R","volume":"69","author":"A Klar","year":"1992","unstructured":"Klar A, Baldassare M, Jessell TM. F-spondin: a gene expressed at high levels in the floor plate encodes a secreted protein that promotes neural cell adhesion and neurite extension. Cell. 1992;69:95\u2013110.","journal-title":"Cell"},{"key":"1180_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1471-4159.2005.03563.x","volume":"96","author":"D Schubert","year":"2006","unstructured":"Schubert D, Klar A, Park M, Dargusch R, Fischer WH. F-spondin promotes nerve precursor differentiation. J Neurochem. 2006;96:444\u201353.","journal-title":"J Neurochem"},{"key":"1180_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fncir.2018.00013","volume":"12","author":"GL Carrillo","year":"2018","unstructured":"Carrillo GL, Su J, Monavarfeshani A, Fox MA. F-spondin is essential for maintaining circadian rhythms. Front Neural Circuits. 2018;12:13.","journal-title":"Front Neural Circuits"},{"key":"1180_CR15","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1073\/pnas.0308655100","volume":"101","author":"A Ho","year":"2004","unstructured":"Ho A, S\u00fcdhof TC. Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. Proc Natl Acad Sci U S A. 2004;101:2548\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1180_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000087379","volume":"26","author":"RA Pyle-Chenault","year":"2005","unstructured":"Pyle-Chenault RA, Stolk JA, Molesh DA, Boyle-Harlan D, McNeill PD, Repasky EA, et al. VSGP\/F-spondin: a new ovarian cancer marker. Tumour Biol. 2005;26:245\u201357.","journal-title":"Tumour Biol"},{"key":"1180_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1247\/csf.20.151","volume":"20","author":"Y Kishiro","year":"1995","unstructured":"Kishiro Y, Kagawa M, Naito I, Sado Y. A novel method of preparing rat-monoclonal antibody-producing hybridomas by using rat medial iliac lymph node cells. Cell Struct Funct. 1995;20:151\u20136.","journal-title":"Cell Struct Funct"},{"key":"1180_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF00708323","volume":"409","author":"W Remmele","year":"1986","unstructured":"Remmele W, Hildebrand U, Hienz HA, Klein PJ, Vierbuchen M, Behnken LJ, et al. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol. 1986;409:127\u201347.","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"1180_CR19","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607\u2013D13.","journal-title":"Nucleic Acids Res"},{"key":"1180_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2108956","volume":"387","author":"RC Sisodia","year":"2022","unstructured":"Sisodia RC, Del Carmen MG. Lesions of the Ovary and Fallopian Tube. N Engl J Med. 2022;387:727\u201336.","journal-title":"N Engl J Med"},{"key":"1180_CR21","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/0008-5472.CAN-15-1050","volume":"75","author":"S Das","year":"2015","unstructured":"Das S, Batra SK. Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy. Cancer Res. 2015;75:4669\u201374.","journal-title":"Cancer Res"},{"key":"1180_CR22","doi-asserted-by":"publisher","first-page":"e02826","DOI":"10.1016\/j.heliyon.2019.e02826","volume":"5","author":"T Muinao","year":"2019","unstructured":"Muinao T, Deka Boruah HP, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019;5:e02826.","journal-title":"Heliyon"},{"key":"1180_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-022-01588-8","volume":"21","author":"JW Zhu","year":"2022","unstructured":"Zhu JW, Charkhchi P, Akbari MR. Potential clinical utility of liquid biopsies in ovarian cancer. Mol Cancer. 2022;21:114.","journal-title":"Mol Cancer"},{"key":"1180_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7326\/0003-4819-121-2-199407150-00009","volume":"121","author":"KJ Carlson","year":"1994","unstructured":"Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med. 1994;121:124\u201332.","journal-title":"Ann Intern Med"},{"key":"1180_CR25","first-page":"227","volume":"69","author":"N Nakagawa","year":"2015","unstructured":"Nakagawa N, Koda H, Nitta N, Nakahara Y, Uno J, Hashimoto T, et al. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis. Acta Med Okayama. 2015;69:227\u201335.","journal-title":"Acta Med Okayama"},{"key":"1180_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","volume":"26","author":"G S\u00f6l\u00e9tormos","year":"2016","unstructured":"S\u00f6l\u00e9tormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, et al. Clinical use of Cancer biomarkers in epithelial ovarian Cancer: updated Guidelines from the European Group on Tumor markers. Int J Gynecol Cancer. 2016;26:43\u201351.","journal-title":"Int J Gynecol Cancer"},{"key":"1180_CR27","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet. 2021;397:2182\u201393.","journal-title":"The Lancet"},{"key":"1180_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/CEJ.0000000000000259","volume":"26","author":"I Zapardiel","year":"2017","unstructured":"Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Macuks R. Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study. Eur J Cancer Prev. 2017;26:346\u201350.","journal-title":"Eur J Cancer Prev"},{"key":"1180_CR29","first-page":"100132","volume":"2","author":"SI Ou","year":"2021","unstructured":"Ou SI, Xiu J, Nagasaka M, Xia B, Zhang SS, Zhang Q, et al. Identification of Novel CDH1-NRG2\u03b1 and F11R-NRG2\u03b1 fusions in NSCLC plus additional novel NRG2\u03b1 fusions in other solid tumors by whole transcriptome sequencing. JTO Clin Res Rep. 2021;2:100132.","journal-title":"JTO Clin Res Rep"},{"key":"1180_CR30","doi-asserted-by":"crossref","unstructured":"Nagasawa S, Ikeda K, Shintani D, Yang C, Takeda S, Hasegawa K et al. Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms23020689"},{"key":"1180_CR31","doi-asserted-by":"publisher","first-page":"e13237","DOI":"10.1111\/cpr.13237","volume":"55","author":"Y Huo","year":"2022","unstructured":"Huo Y, Yang J, Zheng J, Xu D, Yang M, Tao L, et al. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Cell Prolif. 2022;55:e13237.","journal-title":"Cell Prolif"},{"key":"1180_CR32","doi-asserted-by":"publisher","first-page":"839880","DOI":"10.3389\/fonc.2022.839880","volume":"12","author":"I Giusti","year":"2022","unstructured":"Giusti I, Di Francesco M, Poppa G, Esposito L, D\u2019Ascenzo S, Dolo V. Tumor-derived extracellular vesicles activate normal human fibroblasts to a Cancer-Associated Fibroblast-Like phenotype, sustaining a Pro-Tumorigenic Microenvironment. Front Oncol. 2022;12:839880.","journal-title":"Front Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-023-01180-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T21:19:12Z","timestamp":1702415952000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-023-01180-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1186\/s13048-023-01180-8","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,13]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Fukushima Medical University (Fukushima, Japan; approval code, 2019\u2009\u2212\u2009311; approval date, Mar 16, 2021; and approval code, 2021-057; approval date, June 16, 2021). The research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards. This study was carried out by an opt-out method. Since it was conducted as a retrospective study using cases with a follow-up period of more than five years, the patients had already died or stopped visiting the hospital. The experimental protocol has been disclosed on the website, and the patients or their representatives were able to decline to participate in the survey if they wanted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}